Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lenvatinib Mesylate

FDA-approved product (capsule, oral), marketed as Lenvima.

Registered studies
23
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Lenvatinib Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Papillary thyroid carcinoma
  • Renal cell carcinoma
  • Thyroid cancer
  • Thyroid carcinoma
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

23registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lenvatinib Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lenvatinib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma

    NCT07571551 · start 2026-05-06

    Registered record
    Registry ID
    NCT07571551
    Conditions
    Clear Cell RCC
    Interventions
    Toripalimab; Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-06
    Completion
    2032-12-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell RCC
    InterventionToripalimab; Lenvatinib
    PhasePhase 2
    Registry statusRecruiting

  • Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

    NCT07282509 · start 2025-12-23

    Registered record
    Registry ID
    NCT07282509
    Conditions
    Advanced Hepatocellular Carcinoma (HCC)
    Interventions
    HA131; Enlonstobart Injection; Pembrolizumab Injection; Lenvatinib Mesilate Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-12-23
    Completion
    2029-02-03
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Hepatocellular Carcinoma (HCC)
    InterventionHA131; Enlonstobart Injection; Pembrolizumab Injection; Lenvatinib Mesilate Capsules
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

    NCT06499610 · start 2024-07-15

    Registered record
    Registry ID
    NCT06499610
    Conditions
    Gastric Cancer
    Interventions
    Irinotecan Hydrochloride Liposome Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-07-15
    Completion
    2027-10-15
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer
    InterventionIrinotecan Hydrochloride Liposome Injection
    PhasePhase 4
    Registry statusNot yet recruiting

  • HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

    NCT06389500 · start 2024-05-01

    Registered record
    Registry ID
    NCT06389500
    Conditions
    Biliary Tract Cancer
    Interventions
    Adebrelimab; Lenvatinib; Hepatic Arterial Infusion Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-05-01
    Completion
    2028-05-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Tract Cancer
    InterventionAdebrelimab; Lenvatinib; Hepatic Arterial Infusion Chemotherapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

    NCT05342194 · start 2023-06-19

    Registered record
    Registry ID
    NCT05342194
    Conditions
    Intrahepatic Cholangiocarcinoma
    Interventions
    Toripalimab; Lenvatinib mesylate capsules; Placebo IV; Oral placebo; Oxaliplatin for injection; Gemcitabine hydrochloride; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-06-19
    Completion
    2027-05-31
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntrahepatic Cholangiocarcinoma
    InterventionToripalimab; Lenvatinib mesylate capsules; Placebo IV; Oral placebo +3 more
    PhasePhase 3
    Registry statusRecruiting

  • Lenvatinib for Advanced Bone and Soft Tissue Sarcoma

    NCT05617859 · start 2023-04-30

    Registered record
    Registry ID
    NCT05617859
    Conditions
    Effectiveness; Sexuality
    Interventions
    Lenvatinib mesylate capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-30
    Completion
    2026-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEffectiveness; Sexuality
    InterventionLenvatinib mesylate capsule
    PhasePhase 2
    Registry statusRecruiting

  • Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)

    NCT06114940 · start 2022-12-20

    Registered record
    Registry ID
    NCT06114940
    Conditions
    Renal Cell Carcinoma (RCC)
    Interventions
    Toripalimab; Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2022-12-20
    Completion
    2026-01-10
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma (RCC)
    InterventionToripalimab; Lenvatinib
    PhasePhase 2
    Registry statusTerminated

  • Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

    NCT05296512 · start 2022-09-23

    Registered record
    Registry ID
    NCT05296512
    Conditions
    Ovarian Clear Cell Carcinoma; Gynecologic Cancer
    Interventions
    Lenvatinib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-09-23
    Completion
    2028-11-15
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Clear Cell Carcinoma; Gynecologic Cancer
    InterventionLenvatinib; Pembrolizumab
    PhasePhase 2
    Registry statusActive not recruiting

  • IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation

    NCT05339581 · start 2022-05-20

    Registered record
    Registry ID
    NCT05339581
    Conditions
    Liver Cancer; Liver Transplant; Complications; Hepatocellular Carcinoma; Portal Vein Thrombosis; Radiotherapy; Complications
    Interventions
    intensity-modulated radiotherapy; Pembrolizumab; Sintilimab; Camrelizumab; Tislelizumab; Lenvatinib Mesylate Capsule
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-05-20
    Completion
    2024-05-31
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cancer; Liver Transplant; Complications; Hepatocellular Carcinoma +3 more
    Interventionintensity-modulated radiotherapy; Pembrolizumab; Sintilimab; Camrelizumab +2 more
    PhaseNot applicable
    Registry statusUnknown

  • Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

    NCT04929392 · start 2022-01-25

    Registered record
    Registry ID
    NCT04929392
    Conditions
    Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastroesophag
    Interventions
    Carboplatin; Endoscopic Biopsy; External Beam Radiation Therapy; Lenvatinib Mesylate; Paclitaxel; Pembrolizumab; Resection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-01-25
    Completion
    2027-04-25
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 +12 more
    InterventionCarboplatin; Endoscopic Biopsy; External Beam Radiation Therapy; Lenvatinib Mesylate +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

    NCT04550624 · start 2021-09-15

    Registered record
    Registry ID
    NCT04550624
    Conditions
    Advanced Biliary Tract Carcinoma
    Interventions
    Pembrolizumab Injection [Keytruda]; Lenvatinib Mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-15
    Completion
    2025-12-02
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Biliary Tract Carcinoma
    InterventionPembrolizumab Injection [Keytruda]; Lenvatinib Mesylate
    PhasePhase 2
    Registry statusCompleted

  • Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

    NCT04887805 · start 2021-07-21

    Registered record
    Registry ID
    NCT04887805
    Conditions
    Advanced Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma
    Interventions
    Lenvatinib Mesylate; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-07-21
    Completion
    2026-11-05
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8 +3 more
    InterventionLenvatinib Mesylate; Pembrolizumab
    PhasePhase 2
    Registry statusActive not recruiting

  • Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

    NCT04393350 · start 2020-06-22

    Registered record
    Registry ID
    NCT04393350
    Conditions
    Kidney Cancer; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
    Interventions
    Lenvatinib; Lenvatinib Mesylate; Pembrolizumab; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-06-22
    Completion
    2026-12-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
    InterventionLenvatinib; Lenvatinib Mesylate; Pembrolizumab; Quality-of-Life Assessment +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer

    NCT05789667 · start 2020-05-27

    Registered record
    Registry ID
    NCT05789667
    Conditions
    Differentiated Thyroid Cancer; Gender
    Interventions
    Lenvatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-05-27
    Completion
    2025-03-31
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDifferentiated Thyroid Cancer; Gender
    InterventionLenvatinib
    PhaseNot recorded
    Registry statusCompleted

  • Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

    NCT03878524 · start 2020-04-01

    Registered record
    Registry ID
    NCT03878524
    Conditions
    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous
    Interventions
    Abemaciclib; Abiraterone; Afatinib; Bevacizumab; Bicalutamide; Biospecimen Collection; Bortezomib; Cabazitaxel; Cabozantinib; Capecitabine; Carboplatin; Celecoxib; Cobimetinib; Copanlisib; Dabrafenib; Dacomitinib; Darolutamide; Dasatinib; Doxorubicin; Durvalumab; Enasidenib; Entrectinib; Enzalutamide; Erlotinib; Everolimus; Fluorouracil; Idelalisib; Imatinib; Ipilimumab; Lenvatinib; Leucovorin; Lorlatinib; Losartan; Nab-paclitaxel; Neratinib; Nivolumab; Olaparib; Oxaliplatin; Palbociclib; Panobinostat; Pembrolizumab; Pertuzumab; Ponatinib; Quality-of-Life Assessment; Regorafenib; Ruxolitinib; Sirolimus; Sorafenib; Sunitinib; Trametinib; Trastuzumab Emtansine; Tretinoin; Vemurafenib; Venetoclax; Vismodegib; Vorinostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-04-01
    Completion
    2020-12-10
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma +19 more
    InterventionAbemaciclib; Abiraterone; Afatinib; Bevacizumab +52 more
    PhasePhase 1
    Registry statusTerminated